This article was originally published in The Gray Sheet
Topics for discussion at the eighth annual Health Industry Manufacturers Association device submissions workshop June 27-29 include FDA's allocation of resources for implementation of the FDA Modernization Act, 510(k) and premarket approval application reengineering initiatives, advertising and promotion, labeling and expedited review. Device center staffers scheduled to speak include: Susan Alpert, director of FDA's Office of Device Evaluation, Phil Phillips, ODE deputy director, and Byron Tart, director, promotion and advertising policy staff. The conference is being held at the Omni Shoreham hotel in Washington, D.C. Contact James Blanchard at 202/434-7231 for additional information...
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.